Novel Quantification Methods for Fluorescence to Detect Progression in Stargardt Disease
Launched by UNIVERSITY OF MICHIGAN · Aug 28, 2012
Trial Information
Current as of July 21, 2025
Terminated
Keywords
ClinConnect Summary
This study will evaluate whether more sophisticated testing and analytic methodologies, including fundus autofluorescence (FAF) and a novel non-invasive method to measure retinal flavoprotein fluorescence (FPF) may be used to better predict Stargardt macular dystrophy progression and monitor treatment effects than conventional modalities such visual acuity and visual field. This method involves the use of novel statistical methods to assess the heterogeneity of fundus autofluorescence images.
Participants will complete 3 visits to the University of Michigan Kellogg Eye Center. Each visit w...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Between the age of 5 and 18 years old
- • Clinical diagnosis of Stargardt Disease
- • Molecular confirmation of Stargardt Disease (with 2 identified mutations in ABCA4)
- • Visual acuity better than 20/100
- Exclusion Criteria:
- • Limited central vision, defined as visual acuity worse than 20/100
- • A diagnosis of any other retinal degenerative disease
About University Of Michigan
The University of Michigan, a leading academic institution renowned for its commitment to advancing healthcare and medical research, serves as a prominent clinical trial sponsor. With a robust infrastructure that supports innovative research initiatives, the university leverages its multidisciplinary expertise to conduct a wide array of clinical trials aimed at improving patient outcomes and advancing medical knowledge. Through its state-of-the-art facilities and collaborative environment, the University of Michigan fosters partnerships between researchers, clinicians, and industry leaders, ensuring the development of cutting-edge therapies and interventions that address pressing health challenges.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Ann Arbor, Michigan, United States
Patients applied
Trial Officials
K. Thiran Jayasundera, MD
Principal Investigator
University of Michigan Kellogg Eye Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials